Prepared for
Diagnostics
Hero Finding
The Market Leader holds dominant adoption in both tissue and liquid biopsy IVD workflows, and a plurality of labs expect established technology leaders to gain further share over the next three years.
Oncology genomics IVD adoption concentrates around a small set of incumbent platforms. The Market Leader sits at dominant adoption levels in both tissue and liquid biopsy IVD with majority volume share among its users. A Challenger occupies a consistent number-two position roughly two tiers below the Market Leader. Three additional vendors form a smaller third tier in the lower end of the adoption range. The forward-looking outlook reinforces consolidation: a plurality of labs expect established technology leaders to gain share, while vendors with narrow panels, slow innovation, or missing regulatory clearances are flagged for share loss.
Majority
Of labs use the Market Leader for tissue-based IVD genomics testing
Majority
Of labs use the Market Leader for liquid biopsy IVD genomics testing
Plurality
Expect established technology leaders to gain share over three years
Majority
Name liquid biopsy as the fastest-growing segment
Study Design
N=70 clinical diagnostics laboratory leaders · AI-moderated mixed-method interviews · oncology genomics IVD programs across North American and European markets.
The sample was designed to capture the full operational decision-making population for oncology genomics IVD: laboratory directors and section chiefs running active programs across academic, community, IDN, and reference lab settings, with both North American and European representation.
Sample segmentation
Academic Medical Center · 32
Community Hospital · 18
Reference Lab · 20
Interview guide · core topics
- Per-lab oncology genomics test volumes: total, IVD-specific, and clinical purpose allocation
- Sample type modality split: tissue-based vs liquid biopsy testing volumes and use case allocation
- In-house vs send-out distribution and the reasons for outsourcing tissue and liquid biopsy work
- IVD kit vs lab-developed test selection drivers, including regulatory compliance and panel flexibility
- Competitive share by vendor: in-house kit adoption, volume allocation, and regional differences
- Send-out provider landscape: tissue and liquid biopsy referral patterns and concentration
- Growth trajectory: 12-month and three-year volume expectations, fastest-growing segments, serial monitoring outlook
- Switching drivers, planned panel and platform changes, and barriers to vendor consolidation
Recruit criteria
- Department head, laboratory director, or operational manager of an active oncology genomics testing program
- Clinical diagnostics laboratory performing patient-level diagnostic testing using commercially available IVD assays
- Decision-maker or significant influencer for assay/panel selection and vendor contracts
- Located in North American or European markets in scope
Key Findings
What the research surfaced for the market assessment.
Six signals defined the TAM picture, the competitive structure, and the three-year growth window for the genomics oncology IVD platform category.
Median
Sub-thousand oncology genomics tests per lab/site per year
Tissue
Modality dominates today's volume mix
Majority
Of testing performed in-house, minority sent out
Majority
Of labs reported IVD volume increase over past 12 months
Majority
Name liquid biopsy as the fastest-growing segment
01
Per-lab volumes anchor a bottom-up TAM: reference labs run roughly 3x community-setting volumes, with measurable academic-medical-center concentration.
The median lab in this sample runs in the low thousands of total genomics tests, with a high majority of those being oncology-focused and a clear majority of those running on commercial IVD assays. Reference labs run roughly three times the volume of community settings and substantially above academic medical centers. North American labs run more oncology genomics than European labs at the median, with slightly higher IVD penetration in North America. Therapy selection at initial diagnosis represents the majority of oncology genomics volume, with progression and relapse making up the remainder.
02
Volume concentrates in three cancer types: lung, breast, and colorectal account for over half of all oncology genomics testing, with liquid biopsy skewing further toward lung.
Lung leads in both tissue and liquid biopsy share, followed by breast and colorectal. Liquid biopsy skews more toward lung and away from colorectal, reflecting blood-based sampling advantages. Hematologic malignancies account for a meaningful share of liquid biopsy volume but a smaller share of tissue. Europe trends broader in cancer type coverage, with notably higher hematologic malignancy support.
03
The Market Leader holds dominant adoption in both modalities, with the largest share concentration inside academic medical centers and reference labs.
The Market Leader shows dominant adoption in academic medical centers and reference labs, with directionally lower adoption in community settings. Among its users, the platform captures a clear majority of tissue IVD volume and liquid biopsy IVD volume. The Challenger occupies a consistent number-two position with a meaningful but materially lower share. Three additional Specialty vendors form a third tier in the lower end of the adoption range.
04
IVD kits are chosen over LDTs for regulatory compliance and accreditation efficiency, particularly in Europe where the IVDR transition is reshaping the build-vs-buy calculus.
Top IVD-over-LDT selection drivers are regulatory compliance and validation ease and cost/reimbursement, with panel flexibility cited as the primary LDT counterargument. Europe cites regulatory compliance more than North America, driven by select Tier-1 European markets. Reference labs cite regulatory burden as the leading reason for choosing commercial IVDs. Cost reduction is the number-one factor for vendor switching, with most organizations requiring a meaningful improvement to justify switching costs.
05
Volume growth is broadly reported across all time horizons, with Europe showing stronger IVD-specific growth than North America.
A majority of labs reported IVD volume increases over the past 12 months and over three years, with comparable expectations for continued growth in the next 12 months and over three years. Europe shows stronger IVD-specific growth: a substantial majority of European respondents report any increase versus a slimmer majority in North America. North American labs are significantly more likely to report flat IVD volume than European labs.
06
Liquid biopsy is the consensus fastest-growing segment, and serial monitoring is poised to multiply per-patient volume from a single test to multiple runs per year.
A clear majority of respondents name liquid biopsy as the fastest-growing segment over the next 12 months, followed by in-house testing and clinical use-case shifts. Liquid biopsy growth expectations are highest among commercial and genomics labs, and more conservative among IDN/Health Systems. Serial monitoring introduces a structural shift from single-test to recurring-testing models, with patients potentially requiring multiple genomics runs per year rather than a single test at diagnosis.
“The Market Leader has such an edge in sequencing technology and such market penetration that it will continue to be a very strong player. We are moving toward broad comprehensive profiling, and it is increasingly difficult to justify the labor and validation cost of maintaining a second workflow when one platform's high throughput allows us to consolidate all the targets.”— Laboratory Director, Reference Lab
Crosstab · Vendor Adoption by Modality
The Market Leader holds the top adoption position in both tissue and liquid biopsy IVD workflows, with a consistent two-tier gap to the rest of the market.
In-house IVD kit adoption rates and median volume share by vendor and modality. The structure is consistent across North American and European geographies, with directional variation in the third tier. Vendor labels are positioning categories, not real names.
| Tissue IVD adoption | Liquid biopsy IVD adoption | Median volume share among users | |
|---|---|---|---|
| Market Leader | Dominant | Dominant | Majority |
| Challenger | Significant | Significant | Meaningful minority |
| Specialty A | Modest | Modest | Smaller share |
| Specialty B | Modest | Modest | Smaller share |
| Specialty C | Modest | Niche | Smaller share |
| Niche players | Limited | n/a | Niche |
N=70 clinical diagnostics laboratoriesMarket Leader gap to Challenger: substantial in both modalitiesPlurality expect established leaders to gain share over three years
Voice of Customer
How clinical laboratory leaders describe the market structure.
Verbatims from AI-moderated interviews across the sample, selected to represent the range of views on competitive share, regulatory drivers, modality shifts, and growth trajectory.
Competitive Edge · Consolidation
“The Market Leader has such an edge in sequencing technology and such market penetration that it will continue to be a very strong player. We expect more consolidation around the incumbents because the throughput economics keep pulling more assays onto a single workflow.”
— Laboratory Director, Reference Lab
Regulatory Driver · IVDR
“For us, the regulatory landscape is really the driver. Under IVDR, validated IVD kits reduce the burden we face compared to developing and maintaining our own LDTs.”
— Molecular Diagnostics Director, European Academic Hospital
Modality Shift · Liquid Biopsy
“Liquid biopsy testing has significantly increased our therapy selection genomics volume by enabling testing when tissue is limited or inaccessible. It is also used more frequently for disease monitoring and detecting resistance mutations.”
— Clinical Operations Director, Academic Cancer Center
Panel Consolidation · Comprehensive Profiling
“The cost of all these tests will continue to fall. Nowadays you would do a comprehensive panel, and it would come with HRD and other signaling. It covers all the small panel tests and PCR tests. The price is coming down so quickly that there is no point doing the small panel tests anymore. You might as well go straight for the comprehensive profile.”
— Laboratory Director, Reference Lab
Send-Out Rationale · Capability Gap
“There are cases where the breadth of profiling required goes beyond what we can deliver in-house, particularly when clinicians want full comprehensive profiling or when a tumor type needs a very special assay. That is when we route to a send-out provider.”
— Department Head, Academic Hospital
Counter-intuitive
Reimbursement, not technology, is the primary gatekeeper for the next wave of growth.
The prevailing assumption inside the platform category is that growth depends on faster sequencers, broader panels, and better bioinformatics. The data shows otherwise. When labs were asked to identify the levers that will determine the pace of market expansion, reimbursement policy emerged as the leading factor, ahead of expanding precision oncology guidelines and systemic resource constraints. Technology maturation came in well behind. North American labs are significantly more focused on reimbursement than European labs. The implication for product strategy is that regulatory clearances and reimbursement coding work, not sequencer specs, are the highest-leverage investments for unlocking the next 12 to 36 months of volume.
Strategic Implications
Three market strategy moves from the research.
What the research team carried into product roadmap, commercial planning, and competitive positioning, grounded in the share data and the three-year growth window.
01
Defend incumbent share inside academic medical centers and reference labs while attacking the community gap.
The Market Leader sits at dominant adoption in academic medical centers and reference labs but materially lower in community settings. Community is also where the Challenger and Specialty vendors compete most effectively. A community-focused commercial motion, sized for smaller per-site volumes and emphasizing accreditation support and reimbursement workflow, is the highest-leverage share defense move over the next 12 to 24 months.
02
Build the liquid biopsy plus serial monitoring product roadmap as the primary growth vehicle for the next three years.
A clear majority of labs name liquid biopsy as the fastest-growing segment, and serial monitoring shifts per-patient volume from one test at diagnosis to multiple runs per year. This is the largest single demand-multiplier in the dataset. The product roadmap should treat liquid biopsy plus serial monitoring as a first-class category with dedicated panel content, validated workflows, and reimbursement support, separate from the tissue-based therapy selection roadmap.
03
Invest in regulatory and reimbursement workflow ahead of sequencer specs.
Reimbursement is the leading gatekeeper for growth, and regulatory compliance is the leading IVD-over-LDT selection driver. The highest-leverage commercial investments are IVD clearances under IVDR and FDA, reimbursement coding support for new indications (especially serial monitoring), and accreditation-aligned validation packages. Sequencer specs and panel breadth are secondary to compliance and economics in the current buying cycle.
Success criteria · 12 months
- Community-segment share gain of 10 percentage points within 18 months
- Liquid biopsy IVD adoption parity with tissue IVD adoption within 24 months
- Serial-monitoring-specific IVD clearance and reimbursement coding in place before competitor launch
- Reference-lab volume share retention above current levels on a three-year horizon
Risk register
| Reimbursement coding lag for serial monitoring | HIGH |
| Challenger community push | HIGH |
| IVDR transition disruption in EU | MED |
| Comprehensive panel commoditization pressure | MED |
| Send-out provider in-housing reversal | LOW |